Testing idebenone to help prevent episodic migraine attacks
Tests idebenone against placebo to prevent episodic migraine in adults aged 18 to 65.
Plain-language title generated from the registry record
Registry title: Idebenone for the Preventive Treatment of Migraine
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04151472, who can take part
Where in China
- Kaiming LiuHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT04151472
- Record updated
- 15 May 2025
- Original description
Idebenone improves energy metabolism similarly to Coenzyme Q10, which is effective in migraine prophylaxis. The investigators compare idebenone (90 mg/day, 270 mg/day) and placebo in 180 migraine patients in a double-blind, randomized, placebo-controlled, multicenter trial to study whether Idebenone is superior to placebo in the prevention of episodic migraine with or without aura.Read full original descriptionShow less
A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine
Idebenone improves energy metabolism similarly to Coenzyme Q10, which is effective in migraine prophylaxis. The investigators compare idebenone (90 mg/day, 270 mg/day) and placebo in 180 migraine patients in a double-blind, randomized, placebo-controlled, multicenter trial to study whether Idebenone is superior to placebo in the prevention of episodic migraine with or without aura.
Inclusion: Clinical diagnosis of episodic migraine; Patients (18-65 years) were eligible if they met International Headache Society (IHS) criteria for episodic migraine with/ without aura with a migraine history 1 year; Two to eight attacks per month, 5 days/month of interval headaches; No over consumption of acute anti-migraine medication; No other prophylactic medication (washout 3 months); No serious organic or psychiatric disease; Only women with contraceptive protection.
Exclusion: Subjects previously discontinued idebenone due to adverse events; Subjects are taking idebenone or had taken idebenone within 14 days prior to enrollment; Clinical diagnosis of chronic migraine; Subjects with continuous headaches.